303 related articles for article (PubMed ID: 34885103)
1. Epigenetic Mechanisms and Therapeutic Targets in Chemoresistant High-Grade Serous Ovarian Cancer.
Matthews BG; Bowden NA; Wong-Brown MW
Cancers (Basel); 2021 Nov; 13(23):. PubMed ID: 34885103
[TBL] [Abstract][Full Text] [Related]
2. Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathways.
Tomar T; de Jong S; Alkema NG; Hoekman RL; Meersma GJ; Klip HG; van der Zee AG; Wisman GB
Genome Med; 2016 Oct; 8(1):107. PubMed ID: 27765068
[TBL] [Abstract][Full Text] [Related]
3. Methylomic Signatures of High Grade Serous Ovarian Cancer.
Cardenas H; Fang F; Jiang G; Perkins SM; Zhang C; Emerson RE; Hutchins G; Keer HN; Liu Y; Matei D; Nephew K
Epigenetics; 2021 Nov; 16(11):1201-1216. PubMed ID: 33289590
[TBL] [Abstract][Full Text] [Related]
4. Genome-wide DNA methylome analysis identifies methylation signatures associated with survival and drug resistance of ovarian cancers.
Chan DW; Lam WY; Chen F; Yung MMH; Chan YS; Chan WS; He F; Liu SS; Chan KKL; Li B; Ngan HYS
Clin Epigenetics; 2021 Jul; 13(1):142. PubMed ID: 34294135
[TBL] [Abstract][Full Text] [Related]
5. Class I-Histone Deacetylase (HDAC) Inhibition is Superior to pan-HDAC Inhibition in Modulating Cisplatin Potency in High Grade Serous Ovarian Cancer Cell Lines.
Bandolik JJ; Hamacher A; Schrenk C; Weishaupt R; Kassack MU
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234549
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic Modifier SETD8 as a Therapeutic Target for High-Grade Serous Ovarian Cancer.
Wada M; Kukita A; Sone K; Hamamoto R; Kaneko S; Komatsu M; Takahashi Y; Inoue F; Kojima M; Honjoh H; Taguchi A; Kashiyama T; Miyamoto Y; Tanikawa M; Tsuruga T; Mori-Uchino M; Wada-Hiraike O; Osuga Y; Fujii T
Biomolecules; 2020 Dec; 10(12):. PubMed ID: 33339442
[TBL] [Abstract][Full Text] [Related]
7. The high-grade serous ovarian cancer metastasis and chemoresistance in 3D models.
Tadić V; Zhang W; Brozovic A
Biochim Biophys Acta Rev Cancer; 2024 Jan; 1879(1):189052. PubMed ID: 38097143
[TBL] [Abstract][Full Text] [Related]
8. Prediction of Chemoresistance-How Preclinical Data Could Help to Modify Therapeutic Strategy in High-Grade Serous Ovarian Cancer.
Wilczyński J; Paradowska E; Wilczyńska J; Wilczyński M
Curr Oncol; 2023 Dec; 31(1):229-249. PubMed ID: 38248100
[TBL] [Abstract][Full Text] [Related]
9. Harnessing Epigenetics for Breast Cancer Therapy: The Role of DNA Methylation, Histone Modifications, and MicroRNA.
Szczepanek J; Skorupa M; Jarkiewicz-Tretyn J; Cybulski C; Tretyn A
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108398
[TBL] [Abstract][Full Text] [Related]
10. Interactions of Histone Deacetylase 6 with DNA Damage Repair Factors Strengthen its Utility as a Combination Drug Target in High-Grade Serous Ovarian Cancer.
Duda JM; Thomas SN
ACS Pharmacol Transl Sci; 2023 Dec; 6(12):1924-1933. PubMed ID: 38107255
[TBL] [Abstract][Full Text] [Related]
11. Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions.
Alkema NG; Wisman GB; van der Zee AG; van Vugt MA; de Jong S
Drug Resist Updat; 2016 Jan; 24():55-69. PubMed ID: 26830315
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive Profiling of Hypoxia-Related miRNAs Identifies miR-23a-3p Overexpression as a Marker of Platinum Resistance and Poor Prognosis in High-Grade Serous Ovarian Cancer.
Todeschini P; Salviato E; Romani C; Raimondi V; Ciccarese F; Ferrari F; Tognon G; Marchini S; D'Incalci M; Zanotti L; Ravaggi A; Odicino F; Sartori E; D'Agostino DM; Samaja M; Romualdi C; Bignotti E
Cancers (Basel); 2021 Jul; 13(13):. PubMed ID: 34283087
[TBL] [Abstract][Full Text] [Related]
13. Biomarkers of platinum resistance in ovarian cancer: what can we use to improve treatment.
van Zyl B; Tang D; Bowden NA
Endocr Relat Cancer; 2018 May; 25(5):R303-R318. PubMed ID: 29487129
[TBL] [Abstract][Full Text] [Related]
14. Verticillin A Causes Apoptosis and Reduces Tumor Burden in High-Grade Serous Ovarian Cancer by Inducing DNA Damage.
Salvi A; Amrine CSM; Austin JR; Kilpatrick K; Russo A; Lantvit D; Calderon-Gierszal E; Mattes Z; Pearce CJ; Grinstaff MW; Colby AH; Oberlies NH; Burdette JE
Mol Cancer Ther; 2020 Jan; 19(1):89-100. PubMed ID: 31909733
[TBL] [Abstract][Full Text] [Related]
15. Promoter Methylation of the
Li XF; Sun HY; Hua T; Zhang HB; Tian YJ; Li Y; Kang S
Front Oncol; 2021; 11():659254. PubMed ID: 34268111
[TBL] [Abstract][Full Text] [Related]
16. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.
Alkema NG; Tomar T; van der Zee AG; Everts M; Meersma GJ; Hollema H; de Jong S; van Vugt MA; Wisman GB
Gynecol Oncol; 2014 Jun; 133(3):591-8. PubMed ID: 24657486
[TBL] [Abstract][Full Text] [Related]
17. Histone methyltransferase SMYD2 selective inhibitor LLY-507 in combination with poly ADP ribose polymerase inhibitor has therapeutic potential against high-grade serous ovarian carcinomas.
Kukita A; Sone K; Oda K; Hamamoto R; Kaneko S; Komatsu M; Wada M; Honjoh H; Kawata Y; Kojima M; Oki S; Sato M; Asada K; Taguchi A; Miyasaka A; Tanikawa M; Nagasaka K; Matsumoto Y; Wada-Hiraike O; Osuga Y; Fujii T
Biochem Biophys Res Commun; 2019 May; 513(2):340-346. PubMed ID: 30955858
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic regulation of RGS2 (Regulator of G-protein signaling 2) in chemoresistant ovarian cancer cells.
Cacan E
J Chemother; 2017 Jun; 29(3):173-178. PubMed ID: 28102109
[TBL] [Abstract][Full Text] [Related]
19. Targeting DNA Repair in Ovarian Cancer Treatment Resistance.
Wong-Brown MW; van der Westhuizen A; Bowden NA
Clin Oncol (R Coll Radiol); 2020 Aug; 32(8):518-526. PubMed ID: 32253106
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
